Filing Flows › Comparisons › HIND vs ALLR
Vyome Holdings vs Allarity Therapeutics: HIND and ALLR compared
Vyome Holdings is the larger company: $27K of revenue in its latest quarter (Q2 2026) against $25K for Allarity Therapeutics (Q1 2026).
Where the money goes: HIND and ALLR
Vyome Holdings (HIND) · Q2 2026
Vyome Holdings, Q2 2026: revenue $27K (-46% year over year), net loss $720K, operating cash flow −$904K. The chart follows the revenue to costs, profit and cash.
Allarity Therapeutics (ALLR) · Q1 2026
Allarity Therapeutics, Q1 2026: revenue $25K, net loss $2.8M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Vyome Holdings (HIND) | Allarity Therapeutics (ALLR) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $27K | $25K |
| Revenue growth, Y/Y | -46% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$720K | −$2.8M |
| Operating cash flow | −$904K | −$4.5M |
Questions
Which is bigger, Vyome Holdings or Allarity Therapeutics?
Vyome Holdings is the larger company: $27K of revenue in its latest quarter (Q2 2026) against $25K for Allarity Therapeutics (Q1 2026).
More: Vyome Holdings earnings · how Vyome Holdings makes money · Allarity Therapeutics earnings · how Allarity Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed May 15, 2026). Fiscal quarters can end on different dates. Not investment advice.